Terms: = Liver cancer AND MYC, c-Myc, 4609, ENSG00000136997
1596 results:
1. Apoptotic Effect of Isoimpertorin via Inhibition of c-myc and SIRT1 Signaling Axis.
Ko HJ; Park SY; Sim DY; Kim SH; Hur S; Lee JH; Kim Y
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673833
[TBL] [Abstract] [Full Text] [Related]
2. Impact of Prospero Homeobox-1 (PROX-1) οn the Oncogenic Phenotypes of Hepatocellular Carcinoma Cells.
Hong JY; Park SY; Park YL; You GR; Yoon JH; Joo YE; Choi SK; Cho SB
Cancer Genomics Proteomics; 2024; 21(3):295-304. PubMed ID: 38670585
[TBL] [Abstract] [Full Text] [Related]
3. liver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-myc.
Bakiri L; Hasenfuss SC; Guío-Carrión A; Thomsen MK; Hasselblatt P; Wagner EF
Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2404188121. PubMed ID: 38657045
[TBL] [Abstract] [Full Text] [Related]
4. Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-myc pathway.
Sun L; He M; Li F; Wu D; Zheng P; Zhang C; Liu Y; Liu D; Shan M; Yang M; Ma Y; Lian J; Xiong H
Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38573832
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic genomic alterations in patients undergoing liver resection for hepatocellular carcinoma.
Nordkild SB; Ahlborn LB; Yde CW; Kugler JM; Klubien J; Akdag D; Willemoe GL; Nielsen SD; Pommergaard HC
Mol Biol Rep; 2024 Mar; 51(1):450. PubMed ID: 38536546
[TBL] [Abstract] [Full Text] [Related]
6. Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma.
Dong R; Wang T; Dong W; Zhu H; Liu Q; Liang H; Chen X; Zhang B; Zhang X
Biomed Pharmacother; 2024 Apr; 173():116366. PubMed ID: 38458013
[TBL] [Abstract] [Full Text] [Related]
7. An integrated investigation of sulfotransferases (SULTs) in hepatocellular carcinoma and identification of the role of SULT2A1 on stemness.
Peng H; Feng K; Jia W; Li Y; Lv Q; Zhang Y
Apoptosis; 2024 Jun; 29(5-6):898-919. PubMed ID: 38411862
[TBL] [Abstract] [Full Text] [Related]
8. LAPTM4B-mediated hepatocellular carcinoma stem cell proliferation and MDSC migration: implications for HCC progression and sensitivity to PD-L1 monoclonal antibody therapy.
Wang H; Zhou Q; Xie DF; Xu Q; Yang T; Wang W
Cell Death Dis; 2024 Feb; 15(2):165. PubMed ID: 38388484
[TBL] [Abstract] [Full Text] [Related]
9. Hepatitis B surface antigen positivity is associated with poor short- and long-term outcomes in patients with diffuse large B-cell lymphoma who received CHOP or R-CHOP.
Zhan Z; Guo W; Wan X; Wang B; Li J; Wang H; Li Z; Huang Y; Young KH; Bai O
Front Immunol; 2024; 15():1324113. PubMed ID: 38318173
[TBL] [Abstract] [Full Text] [Related]
10. Alterations in the gut microbiota and their metabolites in human intestinal epithelial cells of patients with colorectal cancer.
Jahani-Sherafat S; Azimirad M; Raeisi H; Azizmohammad Looha M; Tavakkoli S; Ahmadi Amoli H; Moghim S; Rostami-Nejad M; Yadegar A; Zali MR
Mol Biol Rep; 2024 Feb; 51(1):265. PubMed ID: 38302841
[TBL] [Abstract] [Full Text] [Related]
11. Nuclear to cytoplasmic transport is a druggable dependency in myc-driven hepatocellular carcinoma.
Deutzmann A; Sullivan DK; Dhanasekaran R; Li W; Chen X; Tong L; Mahauad-Fernandez WD; Bell J; Mosley A; Koehler AN; Li Y; Felsher DW
Nat Commun; 2024 Feb; 15(1):963. PubMed ID: 38302473
[TBL] [Abstract] [Full Text] [Related]
12. FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-myc in colorectal cancer.
Li H; Zheng N; Guo A; Tang W; Li M; Cao Y; Ma X; Cao H; Ma Y; Wang H; Zhao S
Cell Death Dis; 2024 Feb; 15(2):107. PubMed ID: 38302412
[TBL] [Abstract] [Full Text] [Related]
13. FBXO8 is a novel prognostic biomarker in different molecular subtypes of breast cancer and suppresses breast cancer progression by targeting c-myc.
Khan AJ; Man S; Abbas M; Liu S; Zhang F
Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130577. PubMed ID: 38301858
[TBL] [Abstract] [Full Text] [Related]
14. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
[TBL] [Abstract] [Full Text] [Related]
15. Stomatin-like protein 2 promotes cell proliferation and survival under 5-Fluorouracil stress in hepatocellular carcinoma.
Li X; Zheng Y; Yu K; Hou S; Cui H; Yin R; Zhou Y; Sun Q; Zhang J; Huang C
Mol Biol Rep; 2024 Jan; 51(1):228. PubMed ID: 38281294
[TBL] [Abstract] [Full Text] [Related]
16. Elongation factor 1A1 regulates metabolic substrate preference in mammalian cells.
Wilson RB; Kozlov AM; Hatam Tehrani H; Twumasi-Ankrah JS; Chen YJ; Borrelli MJ; Sawyez CG; Maini S; Shepherd TG; Cumming RC; Betts DH; Borradaile NM
J Biol Chem; 2024 Mar; 300(3):105684. PubMed ID: 38272231
[TBL] [Abstract] [Full Text] [Related]
17. TIF1γ and SMAD4 regulation in colorectal cancer: impact on cell proliferation and liver metastasis.
Wu Y; Yu B; Ai X; Zhang W; Chen W; Laurence A; Zhang M; Chen Q; Shao Y; Zhang B
Biol Chem; 2024 Apr; 405(4):241-256. PubMed ID: 38270141
[TBL] [Abstract] [Full Text] [Related]
18. Unraveling the Role of RNA-Binding Proteins, with a Focus on RPS5, in the Malignant Progression of Hepatocellular Carcinoma.
Zhou C; Wu Q; Zhao H; Xie R; He X; Gu H
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255847
[TBL] [Abstract] [Full Text] [Related]
19. Integrative analysis of disulfidptosis and immune microenvironment in hepatocellular carcinoma: a putative model and immunotherapeutic strategies.
Yang T; Liu J; Liu F; Lei J; Chen S; Ma Z; Ke P; Yang Q; Wen J; He Y; Duan J; Zeng X
Front Immunol; 2023; 14():1294677. PubMed ID: 38235128
[TBL] [Abstract] [Full Text] [Related]
20. Identification of peanut skin components for treating hepatocellular carcinoma via network pharmacology and in vitro experiments.
Li S; Liu W; Wang TT; Chen TQ; Guo JC
Chem Biol Drug Des; 2024 Jan; 103(1):e14428. PubMed ID: 38230768
[TBL] [Abstract] [Full Text] [Related]
[Next]
